Yuji Komada

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

N. Hayashi, N. Izumi, T. Okanoue, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

N. Hayashi, Mai Kato, Yuji Komada, 2013, Journal of Gastroenterology.

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin

M. Nakayama, K. Fukushima, Yuji Komada, 2015, Hepatology International.

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.

N. Hayashi, N. Izumi, T. Okanoue, 2014, Journal of hepatology.

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies

N. Hayashi, N. Izumi, T. Okanoue, 2014, Journal of Gastroenterology.